ID   WNK1_HUMAN              Reviewed;        2382 AA.
AC   Q9H4A3; C5HTZ5; C5HTZ6; C5HTZ7; O15052; P54963; Q4VBX9; Q86WL5;
AC   Q8N673; Q9P1S9;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   02-NOV-2010, entry version 103.
DE   RecName: Full=Serine/threonine-protein kinase WNK1;
DE            EC=2.7.11.1;
DE   AltName: Full=Erythrocyte 65 kDa protein;
DE            Short=p65;
DE   AltName: Full=Kinase deficient protein;
DE   AltName: Full=Protein kinase lysine-deficient 1;
DE   AltName: Full=Protein kinase with no lysine 1;
DE            Short=hWNK1;
GN   Name=WNK1; Synonyms=KDP, KIAA0344, PRKWNK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   CHROMOSOMAL LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808.
RC   TISSUE=Heart;
RX   MEDLINE=21455683; PubMed=11571656; DOI=10.1038/sj.onc.1204726;
RA   Verissimo F., Jordan P.;
RT   "WNK kinases, a novel protein kinase subfamily in multi-cellular
RT   organisms.";
RL   Oncogene 20:5562-5569(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND
RP   ILE-1808.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   MEDLINE=20127920; PubMed=10660600; DOI=10.1074/jbc.275.6.4311;
RA   Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J.,
RA   Morris J.D.H.;
RT   "PSK, a novel STE20-like kinase derived from prostatic carcinoma that
RT   activates the JNK MAPK pathway and regulates actin cytoskeletal
RT   organisation.";
RL   J. Biol. Chem. 275:4311-4322(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE
RP   SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=14645531; DOI=10.1128/MCB.23.24.9208-9221.2003;
RA   Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M.,
RA   Corvol P., Jeunemaitre X.;
RT   "Multiple promoters in the WNK1 gene: one controls expression of a
RT   kidney-specific kinase-defective isoform.";
RL   Mol. Cell. Biol. 23:9208-9221(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND
RP   VARIANTS PRO-1056 AND SER-1506.
RC   TISSUE=Brain;
RX   MEDLINE=97349984; PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [7]
RP   SEQUENCE REVISION TO N-TERMINUS.
RX   MEDLINE=22158633; PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION.
RX   MEDLINE=90004678; PubMed=2507249;
RA   Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.;
RT   "Nucleoplasmic and cytoplasmic glycoproteins.";
RL   Ciba Found. Symp. 145:102-118(1989).
RN   [9]
RP   DISEASE.
RX   MEDLINE=21390047; PubMed=11498583; DOI=10.1126/science.1062844;
RA   Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K.,
RA   Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W.,
RA   Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H.,
RA   Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.;
RT   "Human hypertension caused by mutations in WNK kinases.";
RL   Science 293:1107-1112(2001).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002; SER-2011;
RP   SER-2012; SER-2032 AND SER-2038, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2029 AND SER-2032, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17693683; DOI=10.1074/mcp.M700120-MCP200;
RA   Tang L.-Y., Deng N., Wang L.-S., Dai J., Wang Z.-L., Jiang X.-S.,
RA   Li S.-J., Li L., Sheng Q.-H., Wu D.-Q., Li L., Zeng R.;
RT   "Quantitative phosphoproteome profiling of Wnt3a-mediated signaling
RT   network: indicating the involvement of ribonucleoside-diphosphate
RT   reductase M2 subunit phosphorylation at residue serine 20 in canonical
RT   Wnt signal transduction.";
RL   Mol. Cell. Proteomics 6:1952-1967(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167 AND SER-174, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1297 AND SER-1300, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978;
RP   SER-2011; SER-2012; SER-2027; SER-2029; SER-2032 AND SER-2121, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-2012 AND
RP   SER-2372, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978 AND SER-2372, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509;
RP   GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808;
RP   LEU-1823; HIS-1957; CYS-2190; LEU-2362 AND TRP-2380.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Controls sodium and chloride ion transport by inhibiting
CC       the activity of WNK4, potentially by either phosphorylating the
CC       kinase or via an interaction between WNK4 and the autoinhibitory
CC       domain of WNK1. WNK4 regulates the activity of the thiazide-
CC       sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation. WNK1
CC       may also play a role in actin cytoskeletal reorganization.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: By hypertonicity. Activation requires
CC       autophosphorylation of Ser-382. Phosphorylation of Ser-378 also
CC       promotes increased activity (By similarity).
CC   -!- SUBUNIT: Interacts with SYT2 (By similarity).
CC   -!- INTERACTION:
CC       P29101:Syt2 (xeno); NbExp=1; IntAct=EBI-457907, EBI-458017;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9H4A3-1; Sequence=Displayed;
CC         Note=Produced by alternative promoter usage;
CC       Name=2;
CC         IsoId=Q9H4A3-2; Sequence=VSP_050638;
CC         Note=No experimental confirmation available;
CC       Name=3; Synonyms=Kidney-specific, Kinase-defective;
CC         IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637;
CC         Note=Produced by alternative promoter usage;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed
CC       in the testis, heart, kidney and skeletal muscle.
CC   -!- PTM: O-glycosylated.
CC   -!- PTM: Phosphorylated upon DNA damage, probably by ATM or ATR.
CC   -!- DISEASE: Defects in WNK1 are a cause of pseudohypoaldosteronism
CC       type II (PHAII) [MIM:145260]. PHAII is an autosomal dominant
CC       disease characterized by severe hypertension, hyperkalemia, and
CC       sensitivity to thiazide diuretics which may result from a chloride
CC       shunt in the renal distal nephron.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. WNK subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- CAUTION: PubMed:2507249 describes a peptide sequence containing a
CC       GlcNAc glycosylated Ser in position 164 while it is an Arg residue
CC       according to others.
CC   -!- CAUTION: Cys-250 is present instead of the conserved Lys which is
CC       expected to be an active site residue. Lys-233 appears to fulfill
CC       the required catalytic function.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/WNK1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ296290; CAC15059.1; -; mRNA.
DR   EMBL; FJ515833; ACS13726.1; -; Genomic_DNA.
DR   EMBL; FJ515833; ACS13727.1; -; Genomic_DNA.
DR   EMBL; FJ515833; ACS13728.1; -; Genomic_DNA.
DR   EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA.
DR   EMBL; AY231477; AAO46160.1; -; mRNA.
DR   EMBL; AB002342; BAA20802.2; -; mRNA.
DR   IPI; IPI00004472; -.
DR   IPI; IPI00397590; -.
DR   IPI; IPI00397592; -.
DR   RefSeq; NP_055638.2; -.
DR   RefSeq; NP_061852.3; -.
DR   UniGene; Hs.656067; -.
DR   UniGene; Hs.719460; -.
DR   ProteinModelPortal; Q9H4A3; -.
DR   SMR; Q9H4A3; 211-480, 226-545.
DR   IntAct; Q9H4A3; 7.
DR   MINT; MINT-4651503; -.
DR   STRING; Q9H4A3; -.
DR   PhosphoSite; Q9H4A3; -.
DR   PRIDE; Q9H4A3; -.
DR   Ensembl; ENST00000252477; ENSP00000252477; ENSG00000060237.
DR   Ensembl; ENST00000315939; ENSP00000313059; ENSG00000060237.
DR   Ensembl; ENST00000340908; ENSP00000341292; ENSG00000060237.
DR   GeneID; 65125; -.
DR   UCSC; uc001qin.2; human.
DR   UCSC; uc001qio.2; human.
DR   UCSC; uc001qip.2; human.
DR   CTD; 65125; -.
DR   GeneCards; GC12P000862; -.
DR   H-InvDB; HIX0010312; -.
DR   HGNC; HGNC:14540; WNK1.
DR   MIM; 145260; phenotype.
DR   MIM; 605232; gene.
DR   Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2.
DR   Orphanet; 88940; Pseudohypoaldosteronism type 2C.
DR   PharmGKB; PA33782; -.
DR   eggNOG; prNOG06337; -.
DR   HOVERGEN; HBG048577; -.
DR   InParanoid; Q9H4A3; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 67340; -.
DR   ArrayExpress; Q9H4A3; -.
DR   Bgee; Q9H4A3; -.
DR   CleanEx; HS_WNK1; -.
DR   Genevestigator; Q9H4A3; -.
DR   GermOnline; ENSG00000060237; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007243; P:intracellular protein kinase cascade; IDA:UniProtKB.
DR   GO; GO:0006811; P:ion transport; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative promoter usage; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Glycoprotein;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Protein kinase inhibitor; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1   2382       Serine/threonine-protein kinase WNK1.
FT                                /FTId=PRO_0000086819.
FT   DOMAIN      221    479       Protein kinase.
FT   NP_BIND     227    235       ATP (By similarity).
FT   ACT_SITE    349    349       Proton acceptor (By similarity).
FT   BINDING     233    233       ATP (By similarity).
FT   MOD_RES      19     19       Phosphoserine.
FT   MOD_RES     167    167       Phosphoserine.
FT   MOD_RES     174    174       Phosphoserine.
FT   MOD_RES     378    378       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     382    382       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1261   1261       Phosphoserine.
FT   MOD_RES    1297   1297       Phosphoserine.
FT   MOD_RES    1300   1300       Phosphoserine.
FT   MOD_RES    1978   1978       Phosphoserine.
FT   MOD_RES    2002   2002       Phosphoserine.
FT   MOD_RES    2011   2011       Phosphoserine.
FT   MOD_RES    2012   2012       Phosphoserine.
FT   MOD_RES    2027   2027       Phosphoserine.
FT   MOD_RES    2029   2029       Phosphoserine.
FT   MOD_RES    2032   2032       Phosphoserine.
FT   MOD_RES    2038   2038       Phosphoserine.
FT   MOD_RES    2121   2121       Phosphoserine.
FT   MOD_RES    2372   2372       Phosphoserine.
FT   VAR_SEQ       1    407       Missing (in isoform 3).
FT                                /FTId=VSP_050634.
FT   VAR_SEQ     408    437       FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKD
FT                                FCSVFVIINSHCCCCPQKDCINE (in isoform 3).
FT                                /FTId=VSP_050637.
FT   VAR_SEQ     792   1037       Missing (in isoform 2).
FT                                /FTId=VSP_050638.
FT   VARIANT     141    141       A -> T (in dbSNP:rs11554421).
FT                                /FTId=VAR_041309.
FT   VARIANT     149    149       A -> V (in dbSNP:rs34880640).
FT                                /FTId=VAR_041310.
FT   VARIANT     419    419       E -> Q (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041311.
FT   VARIANT     509    509       I -> T (in dbSNP:rs34728563).
FT                                /FTId=VAR_041312.
FT   VARIANT     527    527       D -> G (in dbSNP:rs34408667).
FT                                /FTId=VAR_041313.
FT   VARIANT     665    665       T -> I (in dbSNP:rs2286007).
FT                                /FTId=VAR_019992.
FT   VARIANT     674    674       T -> A (in dbSNP:rs11833299).
FT                                /FTId=VAR_041314.
FT   VARIANT     823    823       H -> R (in dbSNP:rs56015776).
FT                                /FTId=VAR_041315.
FT   VARIANT    1056   1056       T -> P (in dbSNP:rs956868).
FT                                /FTId=VAR_059033.
FT   VARIANT    1199   1199       E -> G (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035640.
FT   VARIANT    1506   1506       C -> S (in dbSNP:rs7955371).
FT                                /FTId=VAR_059034.
FT   VARIANT    1546   1546       A -> V (in dbSNP:rs56351358).
FT                                /FTId=VAR_041316.
FT   VARIANT    1799   1799       Q -> E (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_035641.
FT   VARIANT    1808   1808       M -> I (in dbSNP:rs12828016).
FT                                /FTId=VAR_041317.
FT   VARIANT    1823   1823       P -> L (in dbSNP:rs17755373).
FT                                /FTId=VAR_041318.
FT   VARIANT    1957   1957       R -> H (in dbSNP:rs36083875).
FT                                /FTId=VAR_041319.
FT   VARIANT    2190   2190       S -> C (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041320.
FT   VARIANT    2362   2362       F -> L (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041321.
FT   VARIANT    2380   2380       R -> W (in dbSNP:rs56262445).
FT                                /FTId=VAR_041322.
FT   CONFLICT    164    164       R -> S (in Ref. 8; AA sequence).
FT   CONFLICT    740    740       Missing (in Ref. 6; BAA20802).
FT   CONFLICT   1836   1836       Missing (in Ref. 6; BAA20802).
SQ   SEQUENCE   2382 AA;  250794 MW;  426785F98A452A0A CRC64;
     MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT
     MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH
     REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP
     ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD
     TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV
     TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP
     TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY
     PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ
     EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM
     VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ
     TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG
     SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG
     QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP
     QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP
     VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL
     QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI
     APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG
     GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS
     DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH
     NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP
     EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV
     SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN
     TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE
     EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI
     VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS
     TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY
     ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS
     QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET
     SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST
     TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL
     RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF
     QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD
     VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP
     FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS
     LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES
     LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV
     LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN
     TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG
     MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT
     GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT
//
